TNGXTango Therapeutics, Inc.

Nasdaq tangotx.com


$ 11.78 $ -0.15 (-1.26 %)    

Tuesday, 27-Aug-2024 09:52:17 EDT
QQQ $ 474.50 $ 0.04 (0.01 %)
DIA $ 412.27 $ 0.01 (0 %)
SPY $ 560.02 $ 0.88 (0.16 %)
TLT $ 97.55 $ -0.02 (-0.02 %)
GLD $ 232.04 $ 0.36 (0.16 %)
$ 11.93
$ 11.93
$ 11.40 x 600
$ 11.84 x 100
$ 11.78 - $ 11.97
$ 5.15 - $ 13.03
425,732
na
1.28B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-27-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-maintains-outperform-on-tango-therapeutics-raises-price-target-to-13

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target fro...

 jefferies-initiates-coverage-on-tango-therapeutics-with-buy-rating-announces-price-target-of-19

Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Pric...

 cantor-fitzgerald-reiterates-overweight-on-tango-therapeutics

Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) with a Overweight.

 hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $13 price ...

 hc-wainwright--co-maintains-buy-on-tango-therapeutics-lowers-price-target-to-13

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price targ...

 guggenheim-maintains-buy-on-tango-therapeutics-lowers-price-target-to-14

Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $16 to...

 barclays-maintains-overweight-on-tango-therapeutics-lowers-price-target-to-13

Barclays analyst Peter Lawson maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and lowers the price target from ...

 tango-therapeutics-shuts-early-stage-cancer-study-due-to-liver-toxicity

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...

 wedbush-maintains-outperform-on-tango-therapeutics-lowers-price-target-to-11

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target fro...

 tango-therapeutics-reports-discontinuation-of-tng348-program-says-grade-34-liver-function-abnormalities-were-observed-in-patients-remaining-on-study-longer-than-eight-weeks

TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a ...

 hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-17-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $17 price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION